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ABSTRACT

Scientific progress thrives with open discussion of new ideas and supporting data. To this end,
researchers traditionally publish their results in scientific papers-papers that contain the new
ideas and the underlying data supporting those ideas. With the advent of large-scale and highthroughput data analysis, however, the creation of scientific databases have replaced the traditional
model. For such publically-funded, data-intensive projects, funding agencies typically require that
all relevant data be made available on a publicly accessible website at the time of the paper's
publication. Against the backdrop of the public accessibility model used in the 1000 Genomes
Project, the author recommends that a modified framework be applied to smaller scale data
collection projects. Such a framework could overcome the data producers' concern for protecting the
data they have created, thereby encouraging researchers to share data from smaller scale studies.

Copyright C 2011 The John Marshall Law School

Cite as Donna M. Gitter, The Application of Data Access Policies Designed
for Genome- Wide Association Studies to Smaller Scale Databases,
10 J. MARSHALL REV. INTELL. PROP. L. 476 (2011).

THE APPLICATION OF DATA ACCESS POLICIES DESIGNED FOR GENOMEWIDE ASSOCIATION STUDIES TO SMALLER SCALE DATABASES
DONNA M. GITTER

I. INTRODUCTION..................................................
........... 477
II. THE 1000 GENOMES PROJECT: GOALS AND CHALLENGES
...................... 478
III. THE SCIENCE OF THE 1000 GENOMES PROJECT
..............................
479
IV. THE DATA ACCESS POLICY OF THE 1000 GENOMES PROJECT.

.................... 481

V. OBSTACLES TO DATA-SHARING AND POTENTIAL SOLUTIONS OFFERED BY THE
TORONTO STATEMENT........................................
.................

483

A. Lack of Recognition of Data Producers
..................................
B. The Challenge of Crafting Appropriate Publication Policies ............
C. The Complexity of Establishing a Suitable Infrastructure ..............

483
485
488

VI. THE NEED FOR RESTRICTED ACCESS DATABASES............................

489

476

[10:476 2011] Data Access Policies Applied to Smaller Scale Databases

477

THE APPLICATION OF DATA ACCESS POLICIES DESIGNED FOR GENOMEWIDE ASSOCIATION STUDIES TO SMALLER SCALE DATABASES
DONNA M. GITTER*

I. INTRODUCTION
Scientific discourse and progress depend upon the open discussion of ideas and
full disclosure of supporting facts. 1 This discussion has traditionally occurred
through the process of publication, which is the primary means by which researchers
achieve recognition for their work. 2 Traditionally, researchers published papers that
combined in one entity both their ideas and the underlying data. 3 With the advent of
large-scale and high-throughput data analyses, however, the creation of scientific
databases replaced the traditional model. 4
Typically, for such data-intensive
projects, funding agencies require that all relevant data must be made available on a
publicly accessible website at the time of the paper's publication.5
The Human Genome Project ("HGP"), completed in 2003, demonstrated to the
scientific community that making data broadly available before publication results in
valuable benefits to the public. 6 This is particularly true where there is a community
of scientists who can use the data more quickly than the data producers themselves,
and in ways not originally anticipated at the outset of the project. 7 One successor to
the HGP is the 1000 Genomes Project, which provides that project data will be
released quickly, prior to publication, into the public domain.8
While the open access approach of the 1000 Genomes Project is the norm for
large-scale, publicly-funded genomic databases, many smaller projects that likewise
produce vast amounts of scientific data nonetheless do not embrace data-sharing. 9
*C Donna M. Gitter 2011. Associate Professor of Law, Baruch College, New York, New York.
J.D., University of Pennsylvania Law School; B.A., Cornell University College of Arts and Sciences.
E-mail: Donna.Gitter@Baruch.cuny.edu. I would like to thank two colleagues at The Australian
National University College of Law for encouraging me to develop this work: Dr. Matthew Rimmer,
Associate Professor, Associate Director of Research, and Associate Director, The Australian Centre
for Intellectual Property in Agriculture; and Alison McLennan, Vice Chancellor's Scholar. A version
of this work will appear in a book they have edited, entitled Intellectual Property and Emerging
Biotechnologies, which will be published in 2011. I would also like to thank the editors of the Review
of Intellectual Property Law of The John Marshall Law School for inviting me to contribute this
work to their symposium "Biotechnology and Health-Related Issues in IP Law."
I Ewan Birney et al., PrepublicationData Sharing, 461 NATURE 168, 168 (2009).
2 Paul N. Schofield et al., Post-publication Sharing of Data and Tools, 461 NATURE 171, 171
(2009).
3 Birney et al., supra note 1, at 168.
4
1d.
5Id.

6Id.
71Id.
8See About the 1000 Genomes Project, 1000 GENOMES, http://www.1000genomes.org/
about#Project~verview (last visited Mar. 25, 2011).
9J.H. Reichman & Paul F. Uhlir, The Public Domain: A Contractually Reconstructed Research
Commons for Scientific Data in a Highly Protectionist Intellectual Property Environment, 66 LAW &
CONTEMP. PROBS. 315, 344 (2003).
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Quite often, researchers involved in "small science," meaning research "performed by
individual investigators or small and autonomous research groups operating outside
large, organized research programs, often with non-federal sources of funding," are
not as influenced by the norms of open access and sharing and instead rely on
informal exchanges of data and samples. 10 Scientific researchers, ethicists, lawyers,
representatives of funding agencies, and journal editors are all actively engaged in
discussions aimed at establishing new scientific norms in order to overcome
reluctance to data-sharing in the research community." Close investigation of the
1000 Genomes Project provides guidance in terms of applying the data-sharing
lessons learned from large-scale, publicly-funded databases to smaller projects. 12

II. THE 1000 GENOMES PROJECT: GOALS AND CHALLENGES

Launched in January 2008, the 1000 Genomes Project aims to develop a new
map of the human genome that will provide an extraordinarily detailed view of
biomedically relevant DNA variations among individuals. 13 A clearer understanding
of these small genetic variations will assist in explaining individual differences in
susceptibility to disease, responses to drugs, and reactions to environmental factors. 14
The 1000 Genomes Project builds upon the HapMap Project, a large-scale, publiclyfunded genomic project that established in 2005 a public database of common genetic
variants in human beings. 15 Using HapMap data and related resources, researchers
have succeeded in identifying more than one hundred regions of the genome
containing genetic variants that are associated with risks of common human diseases
such as diabetes, coronary artery disease, and prostate and breast cancer. 16 The goal
of the 1000 Genomes Project is to study these genetic differences in greater depth,
thereby increasing the ability of researchers to discern the causal relationships
between genetic variations and human disease.1 7 Ultimately, the 1000 Genomes
Project will expedite efforts to diagnose, treat, and prevent human diseases.1 8
Like the HapMap Project, the 1000 Genomes Project relies upon a combination
of public and private support, along with the expertise of an international consortium
of research teams. 19 The research teams for the 1000 Genomes Project will sequence
the genomes of at least one thousand people worldwide in order to create a highly
detailed database cataloguing human genetic variation. 20 As with other large-scale,
publicly funded genomic projects, data from the 1000 Genomes Project will be made
10See id. at 322-23.

11See Birney et al., supra note 1, at 168-69.
12See id. at 169.
13International Consortium Announces the 1000 Genomes Project, NAT'L INSTS. HEALTH (Jan.

22, 2008),
http://www.nih.gov/news/health/jan2008/nhgri-22.htm.
4
1

Id.

See generally Int'l HapMap Consortium, A Haplotype Map of the Human Genome, 437
NATURE 1299 (2005) (analyzing data collected from phase one of the HapMap Project).
16InternationalConsortium Announces, supra note 13.
17 See About the 1000 Genomes Project, supra note 8.
18 International Consortium Announces, supra note 13.
19Id.; see Three Sequencing Companies Join 1000 Genomes Project, NAT'L INSTS. HEALTH (June
11, 2008), http://www.nih.gov/news/health/jun2008/nhgri-1 1.htm.
20Three Sequencing Companies Join, supra note 19.
15
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available as rapidly as possible to the international scientific community via release
into freely accessible public databases. 2 1 The quantity of data will be immense,
posing great challenges for the experts in the fields of bioinformatics and statistical
genetics. 22 According to Dr. Gil McVean of the University of Oxford in England, one
of the co-chairs of the consortium's analysis group: "At six trillion bases, the 1000
Genomes Project will generate sixty-fold more sequence data over its three-year
course than have been deposited into public databases over the past twenty-five
years." 23 Certainly, the 1000 Genomes Project Consortium faces a significant
challenge in devising the most effective way to analyze this overwhelming quantity of
data. 24 What is more, the consortium must ensure that its data access policy will
make the data available to the maximum number of users, while simultaneously
permitting researchers to seek intellectual property protection that will foster
innovation. 25

III. THE SCIENCE OF THE 1000 GENOMES PROJECT

A gene is the basic physical and functional unit of heredity for humans and
almost all other organisms. Genes are made up of DNA, which is composed in part of
chemical compounds called bases. 26 Genes cause the body to make molecules called
proteins that guide bodily functioning. 27 In humans, genes vary in size from a few
hundred DNA bases to more than two million bases. 28 The Human Genome Project
has estimated that humans have between 30,000 and 40,000 genes. 29
The DNA sequence of any two people is 99.9 percent identical, with very small
genetic variations proving quite significant in terms of an individual's susceptibility
to disease or response to pharmaceuticals. 30 Sites in the DNA sequence where
individuals differ at a single DNA base are called single nucleotide polymorphisms
("SNPs"). 31 Sets of nearby SNPs on the same chromosome are inherited in blocks
called haplotypes. 32 While a haplotype block may contain a large number of SNPs,
researchers are able to uniquely identify a haplotype by using a few SNPs, called tag
SNPs. 33
21IternationalConsortium Announces, supra note 13.
22 Id.
23 Id.

24Id.; see also Three Sequencing Companies Join, supra note 19; John M. Conley et al.,
Enabling Responsible Public Genomics, 20 HEALTH MATRIX 325, 329-34 (2010).
25Three Sequencing Companies Join, supra note 19; see The 1000 Genomes Project
Consortium, A Map of Human Genome Variation from Population-Scale Sequencing, 467 NATURE
1061, 1062 (2010).
26 LEROY WALTERS & JULIE GAGE PALMER, THE ETHICS OF HUMAN GENE THERAPY 5 (1997).
271d. at 4.
28
1d. at 5-7.

29Donna M. Gitter, International Conflicts Over Patenting Human DNA Sequences in the
United States and the European Union: An Argument for Compulsory Licensing and a Fair-Use
Exemption, 76 N.Y.U. L. REV. 1623, 1633 (2001).
30InternationalConsortium Announces, supra note 13.
31 International
HapMap
Project,
NAT'L
HUM.
GENOME
RES.
INST.,
http://www.genome.gov/10001688 (last visited Mar. 25, 2011).
321d4
3 J
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The HapMap is a map of the haplotype blocks. 34 Its value lies in the fact that
the HapMap reduced the number of SNPs required to examine the entire genome for
association with a phenotype from the ten million SNPs that exist to roughly 500,000
tag SNPs. 35
Thus, researchers can now locate much more efficiently and
comprehensively the regions of the genome with genes that affect disease, because it
is not necessary to study more SNPs than necessary. 36
The HapMap catalogue, however, identifies only those genetic variations that
occur in at least five percent of the population. 37 The 1000 Genomes Project will use
new sequencing technologies to "produce a catalogue of variants present at 1 percent
or greater frequency in the human population across most of the genome, and down
to 0.5 percent or lower within genes." 38 This will permit researchers to gain a better
understanding of some diseases that arise less often. 39
The 1000 Genomes Project will also surpass the HapMap Project in that it will
map not only SNPs, the single-letter differences in people's DNA, but also map larger
differences in genome structure called structural variants. 40 Structural variants are
rearrangements, deletions, or duplications of segments of the human genome which
are believed to be associated with predisposition to conditions such as mental
retardation and autism. 41
In order to achieve its scientific goals, the 1000 Genomes Project will sequence
the genomes of at least one thousand individuals who gave informed consent for their
DNA to be analyzed and placed in public databases. 42 In fact, the first thousand
samples will come from those used for the HapMap and from additional samples in
the extended HapMap set. 43 These participants are drawn from a geographically
wide-ranging group of people of African, East Asian, and European descent. 44 In
addition, an effort began in 2010 to expand data collection to include individuals of
Hispanic and African-American descent. 45 All of the research participants will
remain anonymous and will not have any individual medical information collected
from them, because the project is intended to catalogue genetic variation rather than
to study the disease profile of the individual research participants. 46 In the future,
researchers will be able to use the resource that is developed from the 1000 Genomes
Project in order to conduct studies of people affected by various diseases. 47
The institutions supporting and conducting the genetic sequencing work of the
1000 Genomes Project are the Wellcome Trust Sanger Institute in England, the
Id
Id

34
35

36Id

37Three Sequencing Companies Join, supra note 19.
38InternationalConsortium Announces, supra note 13.
39Three Sequencing Companies Join, supra note 19.
40InternationalConsortium Announces, supra note 13.
41 Id.
42Id

Id.

43

Id.
45Julia Karow, 1000 Genomes Project to Sequence Nearly 1,000 More Samples by Early 2010;
New Samples Collected, GENOMEWEB (Sept. 8, 2009), http://www.genomeweb.com/sequencing/1000genomes-project-sequence-nearly- 1000-more-samples-early-20 10-new-samples-co.
46 IneratiGOnal Consortium Announces, supra note 13.
44

47
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Beijing Genomics Institute in China, and the National Human Genome Research
Institute, part of the National Institutes of Health ("NIH") in the United States. 48
Most of the funding for the 1000 Genomes Project, which will cost between U.S. $30
to $50 million, will come from the existing sequencing budgets of the participating
institutes. 49 In addition, three private U.S. firms that have pioneered development of
new sequencing technologies are contributing a significant portion of the sequence
data, indicating their belief in the value of the large datasets to be produced and
made available through publicly accessible databases.5 0 Indeed, these firms, 454 Life
Sciences, a Roche Company; Applied Biosystems, an Applera Corp. business; and
Illumina Inc., like all other participants in the 1000 Genomes Project, have consented
to the open access policies established by the 1000 Genomes Project Steering
Committee. 51 These policies include "rapid public release of the data; a prohibition
on project participants gaining early access to the data; an intellectual property
policy that precludes any participants from controlling the information provided by
the project or filing for intellectual property rights in the sequences they produce;
regular progress reporting; and coordination of scientific publications with the rest of
the consortium." 52

IV. THE DATA ACCESS POLICY OF THE 1000 GENOMES PROJECT

In order to advance research and encourage international scientific
collaboration, participants in large-scale, publicly-funded sequencing projects have
adopted broad data-sharing policies. 53 In February 1996, at the First International
Strategy Meeting on Human Genome Sequencing in Bermuda, representatives of
laboratories involved in human genome sequencing and of funding agencies
unanimously agreed to implement the Bermuda Statement, an international
agreement favoring release into the public domain of genetic databases achieved
through public funding. 54 The Bermuda Statement provides that "all human genomic
sequence information, generated by centres funded for large scale human sequencing,
should be freely available and in the public domain in order to encourage research
and development and to maximize its benefit to society."5 5 One of the fundamental
requirements of the Bermuda Statement is the stipulation that sequences longer
than 1,000 base pairs must be made freely available to the public, preferably within
twenty-four hours of generation. 56 For the HGP, the highest profile data set rapidly
released before publication, the international sequencing centers involved in the
Id.
49Jocelyn Kaiser, A Plan to Capture Human Diversity in 1000 Genomes, 319 SC. 395, 395
(2008).
50 Three Sequencing Companies Join, supra note 19.
51 Id.
48

52Id

53Schofield et al., supra note 2, at 171.
54See Summary of Principles Agreed at the First International Strategy Meeting on Human
Genome Sequencing (held in Bermuda on Feb. 25-28, 1996), http://www.orn1.gov/sci/techresources/
HumanGenome/research/bermuda.shtml# 1 [hereinafter Bermuda Statement].
56 Bryn

Nelson, Empty Archives, 461 NATURE 160, 162 (2009).
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HGP retained the right to be the first to describe and analyze their complete data
sets in peer-reviewed publications, in return for the early release of their data.5 7
According to its proponents, the Bermuda Statement data release policy fosters
independent checking of the sequence data by other researchers, 5 8 leading to huge
gains in life sciences research. 59 With respect to the HGP, this policy resulted in the
publication of new information about thirty genes associated with disease even prior
to the publication of the draft sequences. 60 In addition, a broad data access policy
prevents publicly funded large-scale sequencing centers from "establishing a
privileged position in the exploitation and control of human sequence information." 61
What is more, the policy also delivers a symbolic message that "the genome belongs
to everybody." 62 When sequencers met again in 2003 in Florida, they reaffirmed
their commitment to the Bermuda Statement in a statement referred to as the Fort
Lauderdale Principles. 63 Consequently, organizations such as the National Institutes
of Health's National Human Genome Research Institute, the Department of Energy,
and the Wellcome Trust require compliance with this policy as a condition of
receiving funding. 64
The 1000 Genomes Project has announced its adherence to the Fort Lauderdale
principles on its website. 65 The site emphasizes that data producers will "release the
Project data quickly, prior to publication, in the expectation that they will be
valuable for many researchers" and that "data users may use the data for many
studies, but are expected to allow the data producers to make the first presentations
and to publish the first paper with global analyses of the data."66
In October 2010, the 1000 Genomes Project published in the journal Nature an
analysis of its completed pilot phase. 67 After the completion of the pilot phase, the
1000 Genomes Project began full-scale studies, which will require an additional two
years. 68 Data from the pilot studies and the full-scale project are freely available on
the project's website, www.1000genomes.org. 69
The data release policy of the 1000 Genomes Project aims to make the genotype
data freely available, while reserving to data producers the right to make the first

57Birney et al., supra note 1, at 168.
58 David R. Bentley, Genomic Sequence Information Should Be Released Immediately and
Freely in the Public Domain, 274 SC. 533, 533 (1996).
9 Id. at 534.
60 Birney et al., supra note 1, at 168.
61 Bermuda Statement, supra note 54.
62Eliot Marshall, Bermuda Rules: Community Spirit, with Teeth, 291 SC. 1192, 1192 (2001).
63See Wellcome Trust, Sharing Data from Large-Scale Biological Research Projects: A System
of Tripartite Responsibility 2 (conference of Jan. 2003), http://www.genome.gov/Pages/Research/
WellcomeReport0303.pdf.
64Lee Rowen et al., PublicationRights in the Era of Open Data Release Policies, 289 SC. 1881,
1881 (2000).
65Use of the Project Data, Presentations and Publications, and Authorship, 1000 GENOMES,
http://www.1000genomes.org/data#DataUse (last visited Mar. 25, 2011).
66 Id.
67 1000 Genomes Project Publishes Analysis of Completed Pilot Phase, NAT'L HUM. GENOME
RES. INST. (Oct. 27, 2010), http://www.genome.gov/27541917; see Map of Human Genome Variation,
supra note 25.
68 Analysis of Completed Pilot Phase, supra note 67.
69 How
to Access 1000 Genomes Data, 1000 GENOMES, http://www.1000genomes.org/
data/#DataAccess (last visited Mar. 25, 2011).
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presentations and to publish the first paper with global analyses of the data. 70
Examination of the 1000 Genomes Project data release policy is particularly
important in light of the recommendation arising from the Fort Lauderdale meeting
that rapid prepublication data release be applied to other data sets created primarily
as a resource for the scientific community.7 1 Experts have observed that data
producers are no longer only large genomics centers, and that, increasingly, smaller
groups are able to produce a large amount of data. 72 Although funding agencies
anticipated that the policies from the HGP and 1000 Genomes Project would be
automatically adopted by these smaller projects, this did not occur. 73 For this reason,
between eighty to one hundred scientists, ethicists, lawyers, representatives of
funding agencies, and journal editors convened at a data release workshop in Toronto
in May 2009, hosted by Genome Canada, in order to discuss the extension of such
data release policies to fields such as proteomics and biobanking. 74 The product of
that meeting was a set of proposals published in Nature in 2009, referred to as "the
Toronto Statement," which aims to establish a set of "best practices" for scientists,
both data producers and data users, as well as funding agencies and journal editors. 75
The Toronto Statement is meant to combat the many factors that inhibit researchers
from sharing their data. 76 Particularly in the realm of small science, these include
data producers' rational desire to be recognized for producing and analyzing data,
thereby preserving their ability to win future research grants; the challenge of
crafting appropriate publication and intellectual property policies; and the
complexity of establishing a suitable infrastructure to house the data.77

V. OBSTACLES TO DATA-SHARING AND POTENTIAL SOLUTIONS
OFFERED BY THE TORONTO STATEMENT

A. Lack of Recognition of Data Producers
In pursuing career advancement, data producers are understandably reluctant
to grant data users access to research results achieved after devoting years of hard
work to "planning a project, securing funding and ethics approval, recruiting the
participants, collecting the data and materials, performing analyses, managing the
collection and infrastructure, controlling technical quality, and generally nourishing
the project through waves of funding and maturation."7 In addition, data producers
70Use of the Project Data, supra note 65.
71Wellcome Trust, supra note 63, at 2.
72Ciara Curtin, When to Share, GENOMEWEB (May 2010), http://www.genomeweb.com/when-

share.
73
74

Id.
Id.

75Birney et al., supra note 1, at 168-70.
76See Donna M. Gitter, The Challenges of Achieving Open Source Sharing of Biobank Data, 29
BIOTECH. L. REP. 623, 625 (2010).

78William W. Lowrance, Access to Collections of Data and Materials for Health Research 24
2006),
http://www.wellcome.ac.uk/stellent/groups/corporatesite/@msh grants/documents!
(Mar.
web document/wtx030842.pdf.

[10:476 2011] The John Marshall Review of Intellectual Property Law

484

fear being "scooped" by data users who may mine data and discover relationships in
it that the producer did not discern. 79 As noted in the Toronto Statement, an
emphasis on early data release gives rise to tension between data producers and
users.8 0 The former typically wish to publish a first description of a data set, while
the latter desire to publish their own analyses of the data.8 1 One way to reduce this
tension is to ensure proper attribution and recognition for data producers. 82
One means of acknowledging the contributions of data producers is to track the
usage and citation of data sets through the use of electronic systems similar to those
used for traditional publications. 83 In order to quantify the usefulness of particular
data sets, Professor Boyle has offered the example of a music site associated with
Creative Commons, 84 known as ccMixter. 85 This site allows users to download music
from the site and remix the samples into new tracks, while simultaneously
maintaining a record of the credits due to each musician. 86 A comparable system
would permit attribution to the appropriate data producer and also allow universities
and funding agencies to track the number of uses, and therefore the value, of a
researcher's data.8 7 This satisfies researchers' desire for attribution, and assists
them in demonstrating their productivity to funding agencies. 88
Another expert, Myles Axton of Nature, has proposed recognizing contributors
via "microattribution," meaning the tracking of researchers' contributions "down to
the very smallest meaningful unit (database record, gene), as opposed to whole
papers as is tradition." 89 Microattribution could minimize the shortcomings of the
Fort Lauderdale Agreement, which Axton has critiqued for failing to reward data
producers with credit for uses of their data. 90 Nor does the Agreement make any
provision for crediting data generators, such as genomics "factory" laboratories. 91 In
addition, notes Axton, the Fort Lauderdale Agreement is not truly enforceable. 92
The Toronto Statement also suggests that funding agencies have a role in
fostering data-sharing. 93 First, the Statement advises that funding agencies should
mandate rapid prepublication data release for projects that "have broad utility, are
large in scale, are 'reference' in character and typically have community 'buy-in."' 94

79

Nelson, supra note 56, at 163.
80 Birney et al., supra note 1, at

169.

81 Id.
82 Id.

at 169-70.
83Nelson, supra note 56, at 163.
84Creative Commons is a nonprofit corporation that aims to facilitate content-sharing in
accordance with the law of copyright.
See About Creative Commons, CREATIVE COMMONS,
http://creativecommons.org/about/ (last visited Mar. 25, 2011).
85 Nelson, supra note 56, at 163 (citing Professor James Boyle of Duke Law School).
86See About, ccMixter, http://ccmixter.org/about (last visited Mar. 25, 2011).
87Nelson, supra note 56, at 163.
88Id.
89Gudmundur A. Thorisson, & Anthony J. Brookes, Meeting Minutes, IRBW2009 Workshop of

May 13-14, 2009, at 5 (Aug. 27, 2009), http://www.gen2phen.org/system/files/private/IRBW2009%/20
meetingo20minutes %20v2.pdf.
90 Id.

a1Id.
93Birney et al., supra note 1, at 169.
94/
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Second, according to the Toronto Statement, funding agencies should make
explicit the requirement for prepublication data release and also become actively
involved throughout the data release process, as demonstrated by the International
HapMap Project and the 1000 Genomes Project, among others. 95 Among the
essential roles for funding agencies is participation in the development of effective
consent, security, access, and governance mechanisms that protect research
participants while encouraging prepublication data release. 96
Third, for projects generating large data sets, the Toronto Statement advises
that funding agencies require that grant applications include data-sharing plans and
undergo peer review, and notes that this is not commonly the case at the present
time. 97 Experts have recommended, in the context of post-publication data release
(and it is equally applicable prepublication) that, where they do not yet exist, clear
criteria should be developed for reviewers of grants to help them evaluate applicants'
plans for sharing data and material. 98 Among examples of good practice cited in this
regard are the NIH, 99 the U.K. Wellcome Trust,100 and the U.K. Medical Research
Council ("MRC"),101 a government-funded research agency akin to the NIH. 102
Commentators note that, for these agencies, "[d]ata-sharing plans are required in
proposals, efforts are made to facilitate sharing, such as putting investigators in
touch with repositories and, for some organizations, compliance is an important
consideration in funding renewal." 103
Fourth, in terms of compliance, funding agencies should clearly express the
rewards for honoring, as well as the sanctions for ignoring, their policies relating to
prepublication data release, and also consistently enforce such policies. 104 One
possibility is to condition grant renewals and promotions to some degree on the
extent to which the investigator shares data.105

B. The Challenge of CraftingAppropriate PublicationPolicies
In light of researchers' desires to protect the data they have gathered and
advance their own careers, efforts to create a culture of data-sharing are inextricably
linked to the question of the optimal publication policies to support data-sharing

95Id.
96 Id.
97 Id.
98Schofield et al., supra note 2, at 172.
9 See generally Final NIH Statement on Sharing Research Data, NAT'L. INSTS. HEALTH (Feb.
26, 2003), http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html.
100See generally Policy on Data Management and Sharing, WELLCOME TRUST (Aug. 2010),
http://www.wellcome.ac.uk/About-us/Policy/Policy-and-position-statements/wtx035043.htm.
101See generally MRC Policy on Data Sharing and Preservation, MED. RES. COUNCIL,
http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Datasharinginitiative/Policy/index.htm
(last visited Mar. 25, 2011).
102About Us, MED. RES. COUNCIL, http://www.mrc.ac.uk/About/Structure/index.htm (last
visited Mar. 25, 2011).
103Schofield et al., supra note 2, at 172.
104 Id
105
Birney et al., supra note 1, at 169.
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efforts. 106 According to the Toronto Statement, although many scholarly works have
been published by third parties reporting research findings based upon data sets
released before publication, few data producers were affected by these publications
that pre-dated their own. 107 Nevertheless, the Toronto Statement proposes that "this
ongoing concern is best addressed by fostering a scientific culture that encourages
transparent and explicit cooperation among data producers, data analysts, reviewers,
and journal editors."10 8
One way of achieving such cooperation is to permit investigators who contribute
data to enjoy some period of exclusivity during which they will have the sole right to
publish analyses of the data. 109 The Toronto Statement declares that data producers
should, as early as possible, and ideally before large-scale data generation begins,
produce a citable statement or "marker paper" in which they describe the data set
and their intentions in respect of analysis and publication. 110 This statement should
include "clear details about the data set to be produced, the associated metadata, the
experimental design, pilot data, data standards, security, quality-control procedures,
expected timelines, data release mechanisms, and contact details for lead
investigators."111 In the event that data producers request a protected time period to
allow them to be the first to publish the data set, data producers should expect this
period to be used only for the publication of a global analysis of the data and to expire
within one year. 112
The NIH and the U.K. Medical Research Council have both adopted a period of
data exclusivity for data producers. 113 The NIH Policy for Sharing of Data Obtained
in NIH Supported or Conducted Genome-Wide Association Studies ("GWAS")
declares that investigators who contribute data to a NIH GWAS data repository will
retain the exclusive right to publish analyses of the dataset for a maximum of twelve
months following its release via the NIH GWAS data repository. 114 During this
period of exclusivity, the NIH grants data access through data access committees to
other investigators, who may analyze the data, but not submit for publication their
analyses or conclusions, until the expiration of the exclusivity period. 115 The NIH
also expects all investigators who access GWAS datasets to acknowledge in all
publications the data producers who conducted the original study, along with the
funding organization that supported the work and the NIH GWAS data repository. 116
Similarly, the U.K. Medical Research Council provides for a period of interim
exclusivity for data producers. 117 The MRC data-sharing policy provides that "[a]
limited, defined period of exclusive use of data for primary research is reasonable." 118
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The U.K. Biobank follows suit, asking researchers to recruit 500,000 participants and
collect their data and samples, in return for which the researchers will gain exclusive
access for a period of time or for research into certain specialty areas. 119 In general,
the purpose of the period of exclusivity is to provide the data producer sufficient time
to produce, organize, document, verify, and analyze the data in preparation for
publication in a scientific journal. 120 After publication, the data is made available
more broadly, either via a publicly available database or via an application system. 121
The Toronto Statement emphasizes that data users should honor the "scientific
etiquette" that allows data producers to publish the first global analyses of their data
set. 122 Participants at the Toronto meeting urged, in cases where the publication
plans of data users overlap the data producers' proposed analyses, that the data
users approach the producers with the goal of "creating a mutually agreeable
publication schedule, such as co-publication or inclusion within a set of companion
papers." 123 In addition, data users should acknowledge any data or materials used
and the originating sources. 124 Some of the potential methods to achieve this include
the addition of metadata tags linking to data and bioresources, or a digital object
identifier for resources in public repositories, which would facilitate the searching of
the literature for specific bioresources. 125 These approaches also offer appropriate
recognition of data producers who comply with data release and deposition policies,
making it possible to offer incentives such as funding contingent upon such
sharing.126
Like data users, journal editors and reviewers also have an important role in the
data-sharing process. 127 Participants at the Toronto meeting recommended that
journals engage actively in the dialogue about rapid prepublication data release, both
in their formal guide to authors and informal instructions to reviewers. 128 Journal
editors should work in tandem with reviewers to consider carefully the specific
policies regarding citation and use of the data that may be associated with certain
large-scale data sets. 129 This will help to raise the quality of analysis and also
promote fairness in citation of published studies. 130
Even a decade before the Bermuda principles, the editors of journals, such as
Nucleic Acids Research, fostered the early development of GenBank and other
genomic repositories by requiring researchers to deposit their data there as a
precondition for publishing. 131 Newer journals, such as the open-access Public
Library of Science journals, have made publication contingent on making the data
"freely available without restriction, provided that appropriate attribution is given
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and that suitable mechanisms exist for sharing the data used in a manuscript." 132
Nature journals require authors to 'make materials, data and associated protocols
1 33
promptly available to readers without preconditions."'
Despite the increased call in many journals for data-sharing, the ability of
journals to compel such behavior is limited. 134 In March 2009, for example, the
journal Epidemiology declared that 'We invite our authors to share their data and
computer code when the burden is minimal,"' according to an editorial in that
issue. 135 Miguel Hernain, an epidemiologist at Harvard University and a co-author of
that editorial, acknowledged the trend toward data-sharing but contended that
forcing a sharing requirement on authors "would be suicidal", especially with
unresolved concerns over patient confidentiality, and would likely cause authors to
submit their papers elsewhere. 136 Moreover, many journals have no written policy on
the availability of either resources or primary data. 137

C. The Complexity of Establishinga Suitable Infrastructure
The Toronto Statement also recommends that funding agencies offer
infrastructural support by funding the creation and long-term maintenance of
databases. 138 Among the costs associated with creating a suitable infrastructure to
house and maintain the data and any associated physical specimens are: the
maintenance of physical premises; the development of appropriate information
technology; the preparation of data for storage or archiving, such as anonymising the
data and documenting the variables; salaries for administrators, managers, and staff;
and the creation and maintenance of an accessible database. 139 These costs are all
ongoing ones. 1 40 Because granting agencies understandably focus primarily on
research, they therefore frequently fail to invest in the infrastructural support
necessary to support their archiving requirements, in a sort of "tragedy of the

commons." 1 41
The internationally collaborative nature of biomedical research exacerbates this
problem by allowing each funding agency to leave the problem to another agency.
Yet overcoming the infrastructure issue is crucial in order to optimize the benefits of
technological progress in the life sciences. 142 Taking human genome sequencing as
one example, one source estimates that the cost of storing all known DNA sequence
information in openly accessible databases costs less than one percent of the sum
necessary to generate such sequence data. 143
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VI. THE NEED FOR RESTRICTED ACCESS DATABASES

Notwithstanding the prescriptions in the Toronto Statement for encouraging
data-sharing, not all data is suitable for an open access approach. 144 Indeed, samples
and data that retain their link with an individual research participant must be
protected with additional procedures. 145 Examples of such data include personal
information such as individual-level genotypic and phenotypic data; exposure to
drugs and environmental factors; and pedigree data, including information about
familial relationships, along with analyses of such data. 146 Experts have offered
several technical and policy approaches to preserve patient privacy. 147
They
recommend, inter alia, the establishment of policies to assess credentials of data
users; the execution of clear contracts with data users that define the appropriate use
of data; formalization of liability rules for misuse of data; and the use of a technical
data management approach that increases the number of research participants
whose data will be aggregated where the data is considered more sensitive. 148
Experts note that subjecting data to access controls erects a barrier that limits the
number of researchers who will reuse the resources. 149 What is more, researchers
may decline to abide by overly complicated data access agreements.150
Nevertheless, restricted access databases are also useful in terms of building
upon the collaborations already established by scientific researchers, particularly
those involved in small science. 15 1 One such biobank is the U.K. DNA Banking
Network ("UDBN"), which is a secondary biobank, meaning that it aggregates and
manages tissue samples and associated data gathered by clinicians who gather the
samples in the course of studying particular diseases. 152
In order to establish UDBN, the U.K. Medical Research Council offered grants to
centers that housed DNA collections. 153 These awards required the collections to be
maintained as "shared national resources," and "made available to collaborators." 154
In addition, awardees were "'required to transfer a portion of each sample"' to the
network and "'to add any genotype data they obtain to the common database."1 55
In granting access to its collections, the UDBN explicitly rejected the
unrestricted "open access" model, instead developing a "fair access" regime, which
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derives inspiration from the 2003 United Nations Educational Scientific and Cultural
Organization ("UNESCO") International Declaration on Human Genetic Data. 156
The UDBN distributes data via the project website to third party researchers, who
apply online for registration. 157 After verifying the researcher's credentials, UDBN
grants access to a restricted area of the website. 15 8 The third party researchers can
then communicate online with the data collectors in order to negotiate
collaboration.159 If a collaborative relationship is successfully negotiated, UDBN
permits the data collector to grant the third party access to fuller data. 160
The fair access model builds upon researchers' willingness to share data with
collaborators, and concomitantly denies access to non-collaborators. 161 This approach
also accepts a collector's right to "exclusive access to his/her collection for the
purposes of the investigational goals stated in the initial collection proposal,"
recognizing that granting a "first mover" advantage is likely to motivate scientific
discovery. 1 62 This model also acknowledges that tensions frequently arise when a
potential collaborator requests data access from a data producer. 163
Thus, the
restricted access model provides a necessary complement to the open access
databank, particularly in the realm of "small science."
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